李小雷，博士，校聘教授，博士研究生導(dǎo)師，博士后合作導(dǎo)師

安徽醫(yī)科大學(xué)“東南學(xué)者”。主持國家自然科學(xué)基金、中國博士后基金面上項(xiàng)目等多項(xiàng)課題研究，主要從事抗炎免疫藥理學(xué)、肝損傷炎癥與修復(fù)、腫瘤免疫相關(guān)研究。主要研究結(jié)果發(fā)表在J. Hepatol., Cell Mol Gastroenterol Hepatol., Hepatol Commun., Oncogene., eLife., Oncoimmunology., Lancet Haematol., J. Hematol Oncol., Cell Mol Immunol.等學(xué)術(shù)期刊，入選北京市科技新星計(jì)劃。

研究方向：抗炎免疫藥理學(xué)、肝損傷炎癥與修復(fù)、腫瘤免疫相關(guān)研究

電子郵箱：lixiaolei@ahmu.edu.cn

主持課題：

1.國家自然科學(xué)基金面上項(xiàng)目, 82470627，2025/01-2028/12

2.國家自然科學(xué)基金面上項(xiàng)目, 82270622, 2023/01-2026/12

3.國家自然科學(xué)基金面上項(xiàng)目, 81672797, 2017/01-2020/12

4.國家自然科學(xué)基金青年基金項(xiàng)目, 31201033, 2013/01-2015/12

5.北京市科技新星計(jì)劃, Z41107001814104, 2014/07-2017/07

6.中國博士后科學(xué)基金第69批面上資助（二等）,2021M690184

部分文章：

1.Dai H, Zhu C, Huai Q, Xu W, Zhu J, Zhang X, Zhang X, Sun B, Xu H, Zheng M,Li X, Wang H. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024 Jun;80(6):913-927.ESI高被引論文

2.Huai Q, Zhu C, Zhang X, Dai H,Li X,Wang H. Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages. Hepatol Commun. 2024 Mar 29;8(4):e0410.

3.Li X,Huai Q, Zhu C, Zhang X, Xu W, Dai H, Wang H. GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of Macrophages to Acquire Anti-Inflammatory Properties. Cell Mol Gastroenterol Hepatol. 2023;16(5):711-734. 

4.Li X, Dai H, Wang Y, Wu Z, Wang H, Qian W, Liang A, Han W. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China. Lancet Haematol. 2022 Dec;9(12):e942-e954.

5.Li X, Su X, Liu R, Pan Y, Fang J, Cao L, Feng C, Shang Q, Chen Y, Shao C, Shi Y. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021 Mar;40(10):1836-1850.